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http://dx.doi.org/10.1016/j.ccr.2013.02.005SUMMARYTumor cells commonly have increased glucose uptake and lactate accumulation. Lactate is produced from
pyruvate by lactate dehydrogenase A (LDH-A), which is frequently overexpressed in tumor cells and is impor-
tant for cell growth. Elevated transcription by c-Myc or HIF1a may contribute to increased LDH-A in some
cancer types. Here, we show that LDH-A is acetylated at lysine 5 (K5) and that this acetylation inhibits
LDH-A activity. Furthermore, the K5-acetylated LDH-A is recognized by the HSC70 chaperone and delivered
to lysosomes for degradation. Replacement of endogenous LDH-A with an acetylation mimetic mutant
decreases cell proliferation andmigration. Importantly, K5 acetylation of LDH-A is reduced in human pancre-
atic cancers. Our study reveals a mechanism of LDH-A upregulation in pancreatic cancers.INTRODUCTION
Alteration in cell metabolism is a common event in tumorigen-
esis, as indicated by the dramatic increase of glucose utilization.
However, the increased glucose uptake in tumor cells often does
not lead to a corresponding increase in oxidative phosphoryla-
tion even in the presence of sufficient oxygen supply. Instead,
glycolysis is highly elevated in most cancer cells. This metabolic
alteration, known as the Warburg effect (Warburg, 1956), is
believed to benefit tumor cells not only by conditioning the
microenvironment, but also by increasing the levels of glycolytic
intermediates, many of which also serve as precursors
for anabolic biosynthesis, to support increased cell growthSignificance
This study uncovers a critical role and the mechanism of acety
which is elevated in cancer cells. Lysine-5 acetylation inhibits LD
increasing degradation by a chaperone-mediated autophagy
with pancreatic cancer initiation. Therefore, acetylation plays a
metabolism.
464 Cancer Cell 23, 464–476, April 15, 2013 ª2013 Elsevier Inc.(Koppenol et al., 2011; Vander Heiden et al., 2009). The fact
that tumor cells have a dramatically increased glucose uptake
has provided the basis for 18F-fluorodeoxyglucose-positron
emission tomography technology, which is widely used for de-
tecting tumors.
The last step of glycolysis is catalyzed by pyruvate kinase (PK),
which converts phosphoenopyruvate to pyruvate. In normal non-
proliferating cells, most, if not all, of pyruvate enters mitochon-
dria, where it is converted to acetyl-CoA by the pyruvate
dehydrogenase complex to fuel the tricarboxylic acid (TCA)
cycle and oxidative phosphorylation for efficient energy produc-
tion. In contrast, in cancer cells, and probably other highly prolif-
erating cells, the influx of pyruvate into mitochondria and thelation in the regulation of lactate dehydrogenase A (LDH-A),
H-A by twomechanisms: decreasing enzymatic activity and
. Moreover, LDH-A lysine-5 acetylation inversely correlates
n important role in the regulation of cell growth and cancer
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Regulation of LDH-A by Acetylation in CancerTCA is not proportional to the increased glucose uptake; instead,
more pyruvate is converted to lactate by lactate dehydrogenase
(LDH). Therefore, a high conversion rate of pyruvate to lactate,
hence high LDH, is commonly observed in cancer cells.
LDH is a homo- or hetero-tetrameric enzyme composed of two
subunits, M and H, encoded by two highly related genes, LDH-A
(also known as LDHM, LDH1, GSD11, and PIG19) and LDH-B
(also known as LDH-H, H-LDH, and LDH2), resulting in five
different isozymes depending on the ratio of the M and H
subunits (M4, M3H1, M2H2, M1H3, and H4). LDH enzyme cata-
lyzes the reversible conversion of pyruvate to lactate usingNAD+
as a cofactor. Although the physiologic significance of lactate
accumulation in tumor cells, a dead-end product in cellular
metabolism, is currently a topic of debate, it has long been
known that many tumor cells express a high level of LDH-A
(Goldman et al., 1964), including non-small cell lung cancer
(Koukourakis et al., 2003), colorectal cancer (Koukourakis
et al., 2006), and breast and gynecologic cancers (Koukourakis
et al., 2009). In many tumors, elevated LDH-A levels have been
correlated with poor prognosis and resistance to chemotherapy
and radiation therapy. Further evidence linking an LDH-A
increase to tumorigenesis comes from the findings that the
LDH-A gene is a direct target of both Myc and HIF transcription
factors (Lewis et al., 1997; Semenza et al., 1996; Shim et al.,
1997). Inhibition of LDH-A by either RNA interference or pharma-
cologic agents blocks tumor progression in vivo (Fantin et al.,
2006; Le et al., 2010; Xie et al., 2009), supporting an important
role of elevated LDH-A in tumorigenesis and LDH-A as apotential
therapeutic target.
We and others have recently discovered that a large number of
non-nuclear proteins, especially those involved in intermediate
metabolism, are acetylated (Choudhary et al., 2009; Kim et al.,
2006; Wang et al., 2010; Zhao et al., 2010). In this report, we
investigated LDH-A acetylation and its functional significance
in tumorigenesis.
RESULTS
LDH-A Is Acetylated at Lysine 5
Eight putative acetylation sites were identified in LDH-A by mass
spectrometry (Figure S1A available online; Choudhary et al.,
2009). Western blotting with anti-acetyllysine antibody showed
that LDH-A was indeed acetylated and its acetylation was
enhanced approximately 3.5-fold after treatment with trichosta-
tin A (TSA), an inhibitor of histone deacetylase HDAC I and II
(Ekwall et al., 1997; Furumai et al., 2001), and nicotinamide
(NAM), an inhibitor of the SIRT family of deacetylases (Avalos
et al., 2005) (Figure 1A).
We then mutated each of eight putative acetylation sites indi-
vidually to glutamine (Q), and examined their acetylation. Muta-
tion of either K5 or K318, but not other lysine residues, to gluta-
mine resulted in a significant reduction in LDH-A acetylation
(Figure S1B). Arginine substitution of K5, but not K318, dramat-
ically decreased the LDH-A acetylation by approximately 70%
(Figure 1B; data not shown), indicating that K5, which is evolu-
tionarily conserved from Caenorhabditis elegans to mammals
(Figure S1C), is a major acetylation site in LDH-A.
We generated an antibody specifically recognizing the K5-
acetylated LDH-A. The specificity of the anti-acetyl-LDH-A (K5)antibody was verified as it recognized the K5-acetylated peptide
but not the unacetylated control peptide (Figure S1D). Western
blotting using this antibody detected ectopically expressed
wild-type, but only weakly recognized the K5R mutant LDH-A
(Figure 1C). Moreover, this antibody detected the acetylated
but not the unacetylated LDH-A that was expressed and purified
from bacteria (Figure 1I). These characterizations demonstrate
the specificity of our anti-acetyl-LDH-A(K5) antibody in recog-
nizing the K5-acetylated LDH-A.
We used the anti-acetyl-LDH-A (K5) antibody to determine
acetylation of endogenous LDH-A. Acetylation of LDH-A could
readily be detected by the antibody. This signal was diminished
by LDH-A knockdown and was completely blocked by the pre-
incubation with the antigen peptide (Figure 1D), confirming the
specificity of the anti-acetyl-LDH-A(K5) antibody. Treatment of
cells with deacetylase inhibitors TSA and NAM strongly
increased K5 acetylation of both endogenously (Figure 1E) and
the ectopically expressed LDH-A (Figure S1E). To quantify
LDH-A acetylation, we employed IEF (isoelectric focusing) to
separate the acetylated protein based on the loss of positive
charge due to lysine acetylation. The spot with highest pI, spot
0, showed the lowest relative acetylation, while the lowest pI
spot 4 had the highest acetylation, indicating that the change
of LDH-A pI is at least in part due to acetylation (Figure 1F).
Assuming that spot 0 represented the unacetylated LDH-A while
spot 4 represented the fully acetylated LDH-A, we estimated that
approximately 20% of the LDH-A is acetylated on lysine 5.
Therefore, a substantial fraction of endogenous LDH-A could
be acetylated.
K5 Acetylation Inhibits LDH-A Enzyme Activity
To test the effect of K5 acetylation, the activity of LDH-AK5R and
LDH-AK5Q mutants was compared with that of wild-type LDH-A.
We found that LDH-AK5Q displayed only 18% of the wild-type
activity, while the LDH-AK5R mutation had a minor effect on the
LDH-A activity (Figure 1G). Consistent with an inhibitory effect
of acetylation on LDH-A activity, inhibition of deacetylases by
NAM and TSA treatment significantly decreased LDH-A enzyme
activity bymore than 60% (Figures 1H andS1F). Moreover, treat-
ment of NAM and TSA had little effect on the activity of either
LDH-AK5Q or LDH-AK5R mutants (Figure 1H).
To definitively demonstrate the effect of K5 acetylation on
LDH-A activity, we employed the system of genetically encoding
Nε-acetyllysine to prepare recombinant proteins in Escherichia
coli (Neumann et al., 2008, 2009). This expression system
produced LDH-A proteins with 100% acetylation at K5 due to
the suppression of the K5-TAG stop codon by the Nε-
acetyllysine-conjugated amber suppressor tRNA. We prepared
both unacetylated and K5-acetylated LDH-A and compared their
enzymatic activity. As shown in Figure 1I, K5-acetylated LDH-A
showed significantly lower activity when compared with the un-
acetylated LDH-A. Collectively, these results demonstrate that
acetylation at lysine 5 inhibits LDH-A activity.
SIRT2 Decreases LDH-A Acetylation and Increases Its
Enzyme Activity
To identify the deacetylase responsible for LDH-A regulation, we
first determined how inhibition of either SIRT or HDAC could
affect LDH-A acetylation at lysine 5. Treatment of cells withCancer Cell 23, 464–476, April 15, 2013 ª2013 Elsevier Inc. 465
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Figure 1. Acetylation at Lys-5 Decreases LDH-A Enzyme Activity
(A) LDH-A is acetylated. Flag-LDH-A was transfected into 293T cells followed by treatment with deacetylase inhibitors TSA and NAM for indicated time. LDH-A
acetylation and protein levels were analyzed by western blot with indicated antibody. Relative ratios of acetylation were calculated from normalizing against Flag-
LDH-A.
(B) Mutation of K5 decreases LDH-A acetylation. The indicated plasmids were transfected into 293T cells and proteins were immunoprecipitated for western
blotting.
(C) Characterization of acetyl-LDH-A (K5) antibody. The indicated plasmids were transfected into 293T cells, acetylation level of immunoprecipitated Flag-LDH-A
was measured by direct western bloting using the acetyl-LDH-A (K5) antibody (a-K5Ac).
(D) Endogenous LDH-A is acetylated on lysine 5. Cell lysate from scramble or LDH-A shRNA knockdown stable cells were probed with indicated antibodies.
(E) Treatment with NAM and TSA increases endogenous LDH-A acetylation; 293T cells were treated with TSA and NAM. Endogenous LDH-A protein levels and
acetylation of K5 were determined by western blotting with indicated antibodies (bottom panel). Relative K5-acetylated LDH-A over total LDH-A protein was
quantified (top panel). Error bars represent ± SD for triplicate experiments.
(F) Quantitative analysis of endogenous LDH-A acetylation at K5 by isoelectric focusing (IEF) analysis; 293T cells lysate were separated by IEF, followed by
western blotting using indicated antibodies. Relative LDH-A K5 acetylation and LDH-A protein levels for each spot were quantified by intensity, and the relative
percentage of each spot is calculated and listed below the western blot panels.
(legend continued on next page)
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Figure 2. SIRT2 Deacetylates LDH-A at K5
and Increases LDH-A Activity
(A) SIRT2 overexpression decreases LDH-A acety-
lation. 293T cells were transfected with indicated
plasmids and LDH-A acetylation was determined by
western blotting.
(B) SIRT2 decreases K5 acetylation and in-
creases LDH-A activity. 293T cells were transfected
with indicated plasmids, Flag-LDH-A was immuno-
precipitated, and LDH-A activity was assayed.
LDH-A activity was normalized against protein
levels. Relative enzyme activities of triplicated
experiments ± SD are presented.
(C) SIRT2 knockdown increases K5 acetylation and
decreases LDH-A activity. 293T cells were trans-
fected with indicated plasmids and SIRT2 siRNA
oligonucleotides. LDH-A was immunoprecipitated
and activity was assayed. LDH-A acetylation at K5
was determined by western blotting. Relative
enzyme activities of triplicate experiments ± SD are
presented.
(D) SIRT2 overexpression increases the activity of
wild-type, but not acetylation-deficient K5R or K5Q
mutant LDH-A. 293T cells were transfected with
indicated plasmids, followed by immunoprecipita-
tion and enzyme assay. Relative enzyme activities of
triplicate experiments ± SD are presented.
(E) The deacetylase activity of SIRT2 is required to
increase LDH-A activity. Sirt2 knockout MEFs were
co-transfected with Flag-LDH-A and SIRT2 wild-
type or the inactive mutant (H187Y). LDH-A was
immunoprecipitated and enzyme activity was as-
sayed. LDH-A activity was normalized against
protein levels. Relative enzyme activities of triplicate
experiments ± SD are presented.
See also Figure S2.
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ylation at K5 (Figure S2), indicating that a SIRT deacetylase is
probably involved in K5 deacetylation. To identify the specific
SIRT, we co-expressed LDH-A with the two cytosolic SIRT de-
acetylases, SIRT1 and SIRT2, and found that SIRT2, but not
SIRT1, decreased LDH-A acetylation (Figures 2A and 2B). Sup-
porting this observation, knocking down SIRT2 significantly
increased K5 acetylation (Figure 2C). Co-expression of SIRT2
increased the activity of the LDH-A by 63% along with the
decreased lysine 5 acetylation (Figure 2B). Conversely, SIRT2
knockdown decreased LDH-A activity by 38% (Figure 2C).
Together, these observations demonstrate a specific and prom-
inent role of SIRT2 in the deacetylation and enzyme activation of
LDH-A.
We also found that SIRT2 co-expression had no significant
effect on the activity of LDH-AK5Q and LDH-AK5R mutants (Fig-(G) K5Q mutant decreases LDH-A enzyme activity. Flag-tagged wild-type and m
precipitation. The enzyme activity was measured and normalized against protein
sented.
(H) NAM and TSA treatment decreases the enzyme activity of wild-type, but not m
in 293T cells and treated with or without NAM and TSA, then purified by immunop
protein level. Relative enzyme activities of triplicate experiments ± SD are prese
(I) Acetylated LDH-A has lower enzyme activity. Recombinant un-acetylated an
encoding Nε-acetyllysine in E. coli. The enzyme activity was measured and
experiments ± SD are presented.
See also Figure S1.ure 2D), indicating that SIRT2 stimulates LDH-A activity mostly
via deacetylation of K5. Furthermore, re-expression of wild-
type SIRT2, but not the inactive H187Y mutant, reduced
LDH-A acetylation and increased LDH-A enzyme activity in
Sirt2 knockout MEFs (Figure 2E). Collectively, these data
support a critical role of SIRT2 enzyme activity in LDH-A regula-
tion by deacetylating lysine 5.
Acetylation at K5 Decreases LDH-A Protein Level
In addition to the effect on LDH-A enzyme activity, NAM and TSA
treatment also led to a time-dependent reduction of LDH-A
protein levels (Figures 3A and S3A).We then determinedwhether
acetylation downregulating of LDH-A protein level occurs at or
after transcription. Quantitative RT-PCR showed that NAM and
TSA treatment had a minor effect on LDH-A mRNA levels (Fig-
ure S3B), indicating a posttranscriptional regulation of LDH-Autant LDH-A protein were expressed in 293T cells and purified by immuno-
level. Relative enzyme activities of triplicate experiments with ± SD are pre-
utant LDH-A. Flag-taggedwild-type andmutant LDH-A protein were expressed
recipitation. The LDH-A enzyme activity was measured and normalized against
nted.
d K5-acetylated LDH-A protein were prepared by the system of genetically
normalized against protein level. Relative enzyme activities of triplicate
Cancer Cell 23, 464–476, April 15, 2013 ª2013 Elsevier Inc. 467
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Figure 3. Acetylation at K5 Decreases
LDH-A Protein Level
(A) NAM and TSA treatment decreases endoge-
nous LDH-A protein level. 293T and HeLa cells
were either untreated or treated with NAM and
TSA for different lengths of time, as indicated. The
steady-state levels of LDH-A protein were deter-
mined by western blotting and normalized against
b-actin.
(B) SIRT2 overexpression decreases endogenous
LDH-A K5 acetylation and increases LDH-A
protein level. Plasmid expressing SIRT2 was
transfected into 293T cells, and endogenous K5
acetylation and LDH-A expression level were
determined by western blotting.
(C) SIRT2 knockdown increases LDH-A K5
acetylation and decreases LDH-A protein level.
siRNA oligo nucleotide targeting SIRT2 was
transfected into 293T cells and the levels of
endogenous LDH-A K5-acetylation, total LDH-A
protein, and SIRT2 protein were determined by
western blotting.
(D) NAM and TSA treatment decreases the
level of wild-type, but not K5R mutant LDH-A.
293T cells stably expressing wild-type and
K5R mutant LDH-A were either untreated or
treated with NAM and TSA. The levels of K5-acetylated and total LDH-A protein were determined by western blotting.
(E) SIRT2 deacetylase activity is required to increase LDH-A protein level. Wild-type or H187Y mutant SIRT2 was expressed in Sirt2 knockout MEFs, and then
endogenous Ldh-A protein level and acetylation at K5 were detected by WB.
(F) SIRT2 knockdown decreases LDH-A activity and protein level in mouse liver. siRNA oligo-nucleotides targetingmouse Sirt2 gene were injected intomouse tail
vein and liver tissue was harvested to determine total LDH-A activity (left panel). SIRT2, LDH-A protein, and K5 acetylation were measured by western blotting
(right panel). Error bars represent ± SD of triplicated experiments.
See also Figure S3.
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LDH-A protein level, we analyzed the effect of SIRT2 overexpres-
sion or knockdown on LDH-A protein. Overexpression of SIRT2
decreased LDH-AK5 acetylation and increased LDH-A protein in
both 293T and pancreatic cancer cell line (Figures 3B and S3C).
Conversely, SIRT2 knockdown increased LDH-A acetylation and
concomitantly decreased the steady-state level of LDH-A
protein (Figure 3C). These results indicate that acetylation may
decrease LDH-A protein. Furthermore, we found that inhibition
of deacetylases decreased the level of wild-type, but not the
K5R mutant (Figure 3D). Based on these results, we propose
that acetylation of K5 destabilizes LDH-A protein.
Next, we investigated the function of SIRT2 in regulation of
LDH-A protein levels. We observed that re-expression of the
wild-type, but not the H187Y mutant SIRT2, increased LDH-A
protein level in Sirt2 knockout MEFs (Figure 3E). In addition,
the relative K5 acetylation (the ratio of K5 acetylation over
LDH-A protein level) was also reduced by expression of the
wild-type, but not the H187Y mutant SIRT2. These data support
the notion that the SIRT2 deacetylase activity plays a role in
regulating LDH-A protein levels. To determine the function of
SIRT2 in LDH-A regulation in vivo, we injected Sirt2 siRNA into
mice via the tail vein, and Sirt2 was efficiently reduced in the
mouse livers by western blot analysis (Figure 3F). We found
that Ldh-A protein levels and activity were significantly
decreased. As expected, the relative K5 acetylation was
increased in Sirt2 knockdown livers (Figure 3F), indicating a crit-
ical function of SIRT2 in LDH-A regulation in vivo.468 Cancer Cell 23, 464–476, April 15, 2013 ª2013 Elsevier Inc.Acetylation Stimulates LDH-A Degradation by
Chaperone-Mediated Autophagy
Inhibition of protein synthesis with cycloheximide (CHX) showed
that LDH-A was a rather stable protein in HeLa cells with a half-
life longer than 8 hr (Figure S4A). Treatment with the proteasome
inhibitor MG132 did not increase LDH-A, but significantly
increased the protein level of PEPCK (Figure 4A), a metabolic
enzyme targeted by the proteasome for degradation (Jiang
et al., 2011). These results indicate that the acetylation-induced
decrease of LDH-A is mediated by a mechanism that is indepen-
dent of proteasome.
Autophagy is a major mechanism in intracellular degradation.
Macro-autophagy is believed to be a nonselective bulk
degradation of intracellular components, whereas chaperone-
mediated autophagy (CMA) is a selective degradation for
proteins, especially those with a long half-life (Mizushima
et al., 2008). We treated cells with leupeptin, an inhibitor of lyso-
somal proteases that can block lysosome-dependent protein
degradation (Jeong et al., 2009), and found that this treatment
caused a significant accumulation of LDH-A protein and K5
acetylation (Figure 4B), confirming the involvement of lysosome
in acetylation-induced LDH-A degradation. Two-dimensional
PAGE analysis showed that leupeptin blocked LDH-A degrada-
tion in cells treated with deacetylase inhibitors (Figure S4B).
Costaining of LDH-A and lysosomal marker also indicated that
a fraction of LDH-A was colocalized with the lysosomal marker
LAMP1 (Figure S4C), consistent with a role of lysosome in
LDH-A degradation.
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Figure 4. Acetylation Promotes LDH-A
Degradation via CMA
(A) LDH-A is not degraded by the ubiquitin-pro-
teasome system (UPS). HeLa cells were treated
with a proteasome inhibitorMG132 and the LDH-A
protein level was analyzed by western blotting.
PEPCK, a known substrate of UPS, was included
as a control.
(B) Leupeptin accumulates K5-acetylated and
total LDH-A protein. HeLa cells were either
untreated or treated with leupeptin for 48 hr. The
levels of total and acetylated LDH-A were deter-
mined by western blotting. LDH-A level was
normalized against b-actin. Error bars represent ±
SD of triplicated experiments.
(C) Serum withdrawal decreases LDH-A protein.
LDH-A level was determined by western blotting
after serum withdrawal for different lengths of
time, as indicated in HeLa cells.
(D) LAMP2A knockdown accumulates LDH-A.
LAMP2A was stably knocked down in HeLa cells
by shRNA. The knockdown efficiency and LDH-A
protein level were determined by western blotting.
(E and F) LAMP2A knockdown blocks the effect of
serum deprivation or NAM and TSA treatment on
LDH-A protein levels. HeLa cell pools stably ex-
pressing LAMP2A shRNA were cultured with or
without serum (E) or NAM and TSA (F). The levels
of K5-acetylated and total LDH-A protein were
determined by western blotting.
(G) Acetylation at K5 increases LDH-A binding to
the HSC70 C-terminal domain in vitro. Recombi-
nant unacetylated and K5-acetylated LDH-A
protein were prepared by the system of genetically
encoding Nε-acetyllysine in E. coli. GST-HCS70
C-terminal domain (from 395 to 533 amino acids)
was used in an in vitro binding assay to pulldown
the purified LDH-A.
(H and I) Inhibition of deacetylases increases
overexpressed or endogenous LDH-A-HSC70
binding. Indicated plasmids were co-transfected
into 293T cells, followed by NAM and TSA treat-
ment. LDH-A-HSC70 binding was determined by
immunoprecipitation-western analysis (H). The
293T cells were untreated or treated with NAM
and TSA (I). Endogenous LDH-A-HSC70 binding
was determined by immunoprecipitation and
western blot analysis.
(J) Inhibition of deacetylases promotes lysosomal
uptake of LDH-A. Flag-tagged LDH-A was im-
munopurified from 293T cells untreated or treated
with deacetylase inhibitors TSA and NAM. The
immunoprecipitated LDH-A was incubated with
the lysosomes isolated from rat liver. Lysosomes
were re-isolated and the associated LDH-A (either
inside or binding to the surface) were determined
by western blotting.
See also Figure S4.
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et al., 1995; Wing et al., 1991). We found that serum starvation
caused adecrease of the steady-state level of LDH-A (Figure 4C),
providing additional evidence for a CMA-dependent degradation
of LDH-A. To rule out macro-autophagy in LDH-A degradation,
we compared the subcellular localization of LDH-A with GFP-
LC-3, which is a marker for autophagosome in the macro-auto-phagy pathway. As shown in Figure S4D, GFP-LC3 and LDH-A
showed different subcellular localizations. Moreover, we deter-
mined LDH-A protein level in Atg5 knockout MEF cells, which
is defective in macro-autophagy, and found that LDH-A protein
levels were comparable in Atg5 wild-type and knockout MEF
cells (Figure S4E).These data indicate that CMA, but not
macro-autophagy, is responsible for LDH-A degradation.Cancer Cell 23, 464–476, April 15, 2013 ª2013 Elsevier Inc. 469
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the lysosomal receptor LAMP2A, which then translocates the
target proteins into lysosome for degradation (Cuervo, 2010).
To provide additional evidence for the role of CMA in LDH-A
degradation, we found that LAMP2A knockdown significantly
increased LDH-A protein (Figure 4D).Moreover, LAMP2A knock-
down also blocked the LDH-A protein reduction caused by either
serum starvation (Figure 4E) or inhibition of deacetylases (Fig-
ure 4F). These data support a model that acetylation promotes
CMA-dependent degradation of LDH-A.
To explore the role of K5 acetylation in LDH-A degradation by
CMA, we examined the interaction between LDH-A and HSC70.
Co-immunoprecipitation showed that the acetylation mimetic
K5Q mutant displayed a much stronger interaction with HSC70
than the wild-type LDH-A (Figure S4G). Fully acetylated or unac-
etylated recombinant LDH-A was prepared by the system of
genetically encoded Nε-acetyllysine in E. coli, and their interac-
tion with HSC70 was examined. The acetylated, but not the un-
acetylated, LDH-A could readily pull down endogenous HSC70
(Figure S4F). The C-terminal domain (amino acid residues 395–
533) is the substrate binding domain of HSC70. We prepared re-
combinant HSC70 C-terminal domain and found it to preferen-
tially pull down acetylated but not unacetylated LDH-A
(Figure 4G). Consistently, treatment of cells with deacetylase
inhibitors TSA and NAM significantly increased the binding
between either ectopically expressed (Figure 4H) or endogenous
LDH-A and HSC70 (Figure 4I). Collectively, these data demon-
strate that LDH-A acetylation, in particular at lysine 5, promotes
its interaction with HSC70.
To determine directly if LDH-A could be taken up by lyso-
somes, we incubated the immunopurified LDH-A with isolated
lysosomes in vitro. The results showed LDH-A binding to isolated
lysosomes (Figure 4J). When lysosomal protease was inhibited,
more LDH-A was found with lysosome, presumably due to the
accumulation of intralysosomal LDH-A. Notably, the LDH-A iso-
lated from TSA- and NAM-treated cells showed more lysosomal
binding/up-taken than LDH-A isolated from untreated cells.
These data are consistent with a model that LDH-A acetylation
increases its interaction with HSC70, binding to and being taken
up by the lysosomes, and leading to its eventual degradation.
K5 Acetylation Impairs the Function of LDH-A in
Supporting Cell Proliferation and Migration
Elevated LDH-A protein levels are frequently seen in different
types of tumors (Goldman et al., 1964). LDH-A is essential for
cancer cell growth in vitro and in vivo (Fantin et al., 2006; Xie
et al., 2009). We therefore investigated the effect of K5 acetyla-
tion of LDH-A on cell proliferation and migration. We knocked
down endogenous LDH-A in the BxPC-3 pancreatic cancer
cell line by shRNA and re-expressed shRNA-resistant wild-
type and K5Q mutant LDH-A to a level similar to endogenous
LDH-A (Figure 5A). Consistent with a previous report (Fantin
et al., 2006), knocking down LDH-A caused a significant
decrease of BxPC-3 cell proliferation that was substantially
rescued by the re-expression of the wild-type LDH-A (Figure 5B).
Notably, the LDH-AK5Q mutant was much less effective than the
wild-type LDH-A in restoring LDH-A—knocking down cell prolif-
eration. Similar effects were observed in 293 cells (Figure S5A).
These results demonstrate that acetylation at Lys 5, which470 Cancer Cell 23, 464–476, April 15, 2013 ª2013 Elsevier Inc.reduces the activity of LDH-A, impairs the ability of LDH-A in
supporting BxPC-3 pancreatic cancer cell proliferation.
We then investigated the effect of LDH-AK5Q mutant on cell
migration. Knockdown of LDH-A decreased cell migration in
BxPC-3 (Figure 5C), 293, and 293T cells (Figures S5B and
S5C), as determined by the wound-healing assay. Re-expres-
sion of wild-type, but not the K5Q mutant LDH-A restored cell
migration, indicated that the acetylation at lysine-5 of LDH-A
inhibits tumor cell migration.
LDH catalyzes the reversible conversion of pyruvate to lactate
with LDH-A and LDH-B kinetically favoring the forward and the
backward reactions, respectively (Ross et al., 2010). To confirm
that the impaired ability of LDH-A K5Q mutant in supporting
BxPC-3 cell proliferation and migration is due to its reduced
catalytic activity, we measured pyruvate and lactate concentra-
tion in LDH-A knocking down cells that were re-introduced with
either wild-type or K5Qmutant LDH-A. We found that the ratio of
lactate to pyruvate was decreased by nearly one-half that of both
intracellular (upper panel) and extracellular (low panel) levels in
cells expressing K5Q mutant compared to cells expressing the
wild-type LDH-A (Figure 5D). These results suggest LDH-A acet-
ylation plays an important role in regulating the conversion of
pyruvate to lactate.
It has been reported that lactate could drive cell migration
(Bonuccelli et al., 2010; Ve´gran et al., 2011). Therefore, we also
determined the effect of lactate on migration in BxPC-3 cells.
Consistently, we found that lactate promoted BxPC-3 cell migra-
tion (Figure S5D). These data indicate that K5 acetylation of
LDH-A decreases lactate production, thereby restraining
BxPC-3 pancreatic cancer cell migration.
To address the biologic significance of K5 acetylation in tumor
growth, we performed xenograft experiments using the BxPC-3
stable cell lines with LDH-A knockdown and re-expression of
shRNA-resistant wild-type or K5Q mutant LDH-A. As shown in
Figures 5E and 5F, the K5Qmutant-expressing BxPC-3 cells dis-
played tumor growth significantly slower than the wild-type
LDH-A-expressing cells. Taken together, these data indicate
that LDH-A K5 acetylation impairs its function in catalyzing pyru-
vate to lactate conversion, and then inhibits cell proliferation and
tumor growth.
K5 Acetylation of LDH-A Is Downregulated in Pancreatic
Cancer
Pancreatic ductal adenocarcinoma cancer (PDAC) is the fourth
leading cause of cancer death, with less than 5% 5 year survival
after diagnosis. Pharmacologic inhibition of LDH-A has been re-
ported to suppress the progression of pancreatic tumors in
a xenograft model (Le et al., 2010). The finding that acetyl-
mimetic substitution at lysine-5 impairs the ability of LDH-A to
support BxPC-3 pancreatic cancer cell proliferation and tumor
growth prompted us to examine both the K5 acetylation and total
LDH-A protein in human cancers. We collected a total of 127
primary human pancreatic cancer samples, including 65 pairs
that had surrounding normal pancreatic ducts tissues. We first
carried out a direct immunoblotting analysis of a panel of 19 pairs
of primary pancreatic tumors (T) and their adjacent normal
tissues (N), for which we were able to obtain sufficient amounts
of proteins. This analysis revealed that, when compared to
normal pancreatic tissues, eight pairs showed a significant
A B
C D
E F
Figure 5. Acetylation Mimetic LDH-AK5Q Mutant Has Reduced Ability to Support Cell Proliferation and Cell Migration
(A) Generation of LDH-A-expressing BxPC-3 stable cell lines. BxPC-3 cells stably knockdown LDH-A and re-express the shRNA-resistant wild-type or K5Q
mutant were established. LDH-A knockdown efficiency and re-expression were determined by western blotting.
(B) LDH-AK5Q is compromised to support cell proliferation. LDH-AWT or LDH-AK5Q cells were seeded in each well. Cell numbers were counted every 48 hr. Error
bars represent cell numbers ± SD for triplicate experiments.
(C) LDH-AK5Q mutant is compromised to support cell migration. BxPC-3 cells as described in panel A were analyzed for migration by a wound-healing assay.
Scale bars are 200 mm.
(D) LDH-AK5Q decreases intracellular and extracellular lactate/pyruvate ratio. LDH-AWT or LDH-AK5Qcells were seeded in each well. Intracellular or extracellular
pyruvate and lactate production were measured according to manufacturer’s protocol (BioVision). Error bars represent ± SD for triplicate experiments.
(E and F) LDH-AK5Q is defective in supporting tumor growth in vivo. Xenograft was performed using the BxPC-3 stable cell lines with LDH-A knockdown and re-
expression of shRNA-resistant wild-type or K5Q mutant LDH-A as indicated. Seven weeks later, mice were sacrificed and tumor weight was measured. The
p value was calculated by paired t test.
See also Figure S5.
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Regulation of LDH-A by Acetylation in Cancerincrease of the steady-state levels of total LDH-A protein without
a corresponding increase of K5 acetylation (Figure 6A). There-
fore, these eight pairs of tumor samples had a decreased ratio
of K5-acetylated versus total LDH-A proteins. Quantification of
six pairs (two pairs exhibiting levels of LDH-A in the normal
tissues too low to be reliably quantified) confirmed that both
the increase of total LDH-A (p < 0.0001) and the decrease in
the ratio of K5-acetylated LDH-A versus total LDH-A proteins
(p = 0.0031) in tumor cells are statistically significant (Figure S6A).
Of the remaining 11 pairs, the total LDH-A protein was increased
in four pairs, unchanged in four pairs, and decreased in three
pairs in tumor tissues when compared to the adjacent normal
tissues (Figure S6B). The ratio of K5-acetylated versus total
LDH-A was not significantly decreased in these 11 pairs.
C-Myc has been implicated in transcription regulation of many
metabolic genes, including LDH-A (Shim et al., 1997). We also
examined c-Myc protein levels in these 19 pairs of pancreatic
tissues. However, we did not find an increase of c-Myc in
pancreatic tumor tissues or a positive correlation between
c-Myc and LDH-A protein levels (Figures 6A and S6B). There-
fore, the reduced LDH-A K5 acetylation correlates with the
increased LDH-A protein levels in the pancreatic tumors.
To substantiate the finding that K5-aetylated LDH-A is signif-
icantly decreased in some pancreatic tumors, we explored the
feasibility of determining the level of both total and K5-acety-
lated LDH-A by immunohistochemistry in paraffin-embedded
tissues to expand our study. The anti-acetyl-LDH-A(K5) anti-
body was characterized by its suitability for immunohistochem-
istry. We found that this antibody could detect strong signals
that were specifically blocked by the acetyl-K5 antigen peptide
in paraffin-embedded tissues (Figure S6C). Taking the advan-
tage of this reagent, we then performed immunohistochemistry
in 108 pancreatic cancer samples, including 46 samples that
had the adjacent normal pancreatic ducts tissues. In most
samples, we observed that the levels of total LDH-A were
higher and the levels of relative K5-acetylated LDH-A were
lower in the tumor tissues than in the adjacent normal tissues
(Figure 6B). Statistical analyses of quantified images indicated
that the differences between tumor and normal tissues in total
LDH-A protein levels (p < 0.0001), in K5-acetylated LDH-A
(p < 0.0001), and in the ratio of K5-acetylated LDH-A versus
total LDH-A proteins (p < 0.0001) are all highly significant,
comparing either the 108 tumor samples to the 51 normalFigure 6. K5-Acetylation of LDH-A Is Downregulated in Pancreatic Ca
(A) Total LDH-A and SIRT2 protein are increased and K5-acetylated LDH-A decre
LDH-A protein, K5 acetylation, SIRT2, and c-Myc in 19 pairs of pancreatic cancer
exhibited clear inverse correlation between K5-acetylated and total LDH-A and
ure S6A for the complete western blotting of the other 11 pairs.
(B and C) Immunohistochemical stainings of K5-acetylated and total LDH-A prote
statistical analysis of all samples is shown in (C). Scale bars are 50 mm. The intens
quantified using theMotic Images Advanced software, followed by statistical analy
tissues were analyzed. The mean value of multiple samples and standard deviat
(D) Immunohistochemical staining of SIRT2 proteins in tumor and adjacent norma
samples is shown. The intensities of SIRT2 proteins were quantified using the Mo
of multiple samples and standard deviation is presented.
(E) LDH-A protein levels show negative correlation with K5 acetylation, and posi
pancreatic cancer tissues that had been examined for all three signals (LDH-A
compared with adjacent tissues. These tumors also exhibited increased SIRT2 a
See also Figure S6.pancreatic ducts samples (Figure 6C), or the 46 tumor samples
with their adjacent normal tissues (Figure S6D). We also found
that SIRT2 expression was increased in pancreatic tumor
tissues compared to adjacent normal tissues (Figures 6A, 6D,
and S6E).
Although more than 100 case tumors were collected, most
pancreatic tumors are very small, and the number of paired
paraffin sections with both tumor and adjacent on the same slide
is hence limited. We determined the levels of LDH-A, K5-acety-
lated LDH-A, and SIRT2 in only 39 paired tissues. Among these
pairs, high LDH-A protein level is found in 37 pairs of tumor
compared with adjacent tissue. These tumors also exhibited
increased SIRT2 and decreased acetylation at K5 as shown in
Figure 6E. The tumor sample analyses demonstrate that
LDH-A protein levels have a negative correlation with K5 acety-
lation and a positive correlation with SIRT2 levels in pancreatic
tumors. These data also indicate that LDH-A and K5 acetylation
may be potential biomarkers for pancreatic tumor.
The development of pancreatic cancer can be divided into
five stages according to their location, size, and metastatic
features: stage 0 (carcinoma in situ found in the lining of the
pancreas), stage I (found only in pancreas with size smaller
[IA] or larger [IB] than 2 cm), stage II (spread to nearby tissue,
either including [IIB] or excluding [IIA] the lymph nodes), stage
III (spread to major blood vessels near the pancreas), and stage
IV (spread to distant organs). To determine whether LDH-A K5-
acetylation level is related to the pancreatic tumor progression,
we analyzed the levels of K5-acetylated as well as total LDH-A
in the panel of 108 pancreatic tumors according to their stages.
LDH-A protein level was significantly increased in all cancer
stages when compared to normal tissues (Figure S6F, left
panel), but no significant difference was detected between
different stages (Figure S6G). The levels of K5-acetylated
LDH-A were decreased significantly in all cancer stages when
compared to normal tissues (Figure S6F, right panel), and there
appeared to be a progressive decrease in the levels of K5-
acetylated LDH-A from stage IA to stage IB (p = 0.009) and
then to stage IIA (p = 0.0068 versus IA, Figure S6H). There
was no significant difference in the levels of K5-acetylated
LDH-A among stages IIA, IIB, III, and IV. Taken together, these
data suggest a possible role of K5 acetylation contributing
to pancreatic cancer initiation, but not progression to the
advanced stages.ncer
ased in pancreatic cancer tissues compared to adjacent tissues. The levels of
and adjacent normal tissues were analyzed by western blotting. Eight pairs that
positive correlation between SIRT2 and total LDH-A are shown. See also Fig-
ins in tumor and adjacent normal tissues. One example is shown in (B) and the
ities of the total (left panel) and K5-acetylated (right panel) LDH-A proteins were
sis. A total of 108 pancreatic cancer tissues and 51 adjacent normal pancreatic
ion are presented.
l pancreatic cancer tissues. The statistical analysis of 99 tumor and 59 normal
tic Images Advanced software, followed by statistical analysis. The mean value
tive correlation with SIRT2 protein in pancreatic tumors. Among the 39 paired
, K5Ac, and SIRT2), 37 cases showed high LDH-A protein levels in tumors
nd decreased acetylation at K5.
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Figure 7. Working Model
Acetylation at K5 inhibits LDH-A enzyme activity
and promotes its lysosomal degradation via CMA.
In pancreatic cancer tissues, SIRT2 deacetylates
LDH-A and increases its activity and protein level,
thereby accelerating glycolysis and lactate
production, leading to increased cell proliferation
and migration. Glc, glucose; Pyr, pyruvate; Lac,
lactate; Ac, acetylation.
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Reprogramming of energy metabolism, including elevated
glycolysis, is a hallmark of cancer (Hanahan and Weinberg,
2011). To support rapid cell growth, glucose uptake and meta-
bolic intermediates for macromolecule biosynthesis are dramat-
ically increased in cancer cells. In particular, glycolysis is highly
elevated. Among the glycolytic enzymes, LDH is unique because
it is essential to maintain high glycolysis rate by regenerating
NAD+ required in early steps in glycolysis (Bui and Thompson,
2006). Moreover, LDH channels pyruvate to lactate instead of
converting it to acetyl-CoA for oxidative phosphorylation,
a commonly observed phenomenon in many tumor cells. In
this study, we uncovered a mechanism of LDH-A regulation
that contributes to its increased protein level and activity to
meet the elevated lactate production in tumor cells (Figure 7).
We demonstrate that acetylation at K5 inhibits LDH-A enzyme
activity and promotes its lysosomal degradation via CMA. In
pancreatic cancer tissues, SIRT2 deacetylates LDH-A and
increases its activity and protein level, thereby accelerating
glycolysis and lactate production, leading to increased cell
proliferation and migration.
LDH-A upregulation is commonly observed in cancers. This is
in part due to transcriptional activation by the increasedMyc and
HIF in cancers. In this study, we report another mechanism in
regulation of LDH-Aprotein levels. Acetylation plays an important
role in posttranslational regulation of LDH-A by twomechanisms.
First, acetylation directly inhibits LDH-A enzymatic activity.
Second, acetylation stimulates CMA-mediated degradation of
LDH-A. Notably, the relative acetylation of LDH-A is reduced in
pancreatic cancer. We propose that the decreased LDH-A acet-
ylation in cancer cells may contribute to the elevated LDH-A
protein levels and activity as well as tumorigenesis (Figure 7).
A key step in CMA regulation is the interaction between chap-
erone HSC70 and target proteins. It has been reported that post-
translation modifications can regulate this process (Cuervo,
2010). For LDH-A, acetylation enhances the interaction between474 Cancer Cell 23, 464–476, April 15, 2013 ª2013 Elsevier Inc.LDH-A and HSC70 (Figure 7). We show
that HSC70 selectively interacts with
acetylated proteins and thereby preferen-
tially promotes lysosome-dependent
degradation of the acetylated LDH-A.
The three-dimensional structure of LDH
indicates that lysine 5 is located in the
N-terminal alpha-helix region of LDH-A,
which is structurally separated from the
catalytic domain (Read et al., 2001).
Therefore, the K5-containing helix canbe available for interaction with other proteins. Chaperone nor-
mally interacts with unfolded proteins that often have an
exposed hydrophobic surface. It is conceivable that lysine acet-
ylation increases surface hydrophobicity of the K5 helix in LDH-A
and therefore promotes its interaction with the HSC70 chap-
erone. Further structural studies will be needed to obtain
a precise understanding of how HSC70 recognizes acetylated
target proteins.
Fantin and colleagues reported that LDH-A knockdown could
inhibit tumor cell proliferation, especially under hypoxia (Fantin
et al., 2006). A unique feature of LDH-A is that it acts at the
end of the glycolytic pathway and catalyzes pyruvate to produce
lactate, which is often accumulated in cancer cells (Figure 7).
Many studies have shown that lactate can condition the micro-
environment, which promotes interaction between cancer cells
and stromal cells, eventually resulting in cancer cell invasion.
Indeed, the ratio of lactate to pyruvate is significantly decreased
in the acetylation mimetic K5Q mutant-expressing cells. More-
over, K5Q mutant is compromised in its ability to support prolif-
eration and migration of BxPC-3 cells, most likely due to the
decreased LDH-A activity. This may potentially explain why
cancer cells have reduced LDH-A acetylation and increased
LDH-A protein levels.
We observed that LDH-A expression positively correlates with
SIRT2 expression in pancreatic cancer tissues, suggesting that
SIRT2 may have oncogenic function in pancreatic cancer.
However, SIRT2 has been reported as a tumor suppressor
gene in a knockout mouse model (Kim et al., 2011). Notably,
SIRT1 has been also suggested to act as both tumor promoter
and suppressor in a context-dependent manner. Therefore, it
is possible that SIRT2 may promote tumor growth under one
circumstance, such as in human pancreatic cancer, and
suppress tumor growth under another circumstance, such as
hepatocellular carcinoma in Sirt2 knockout mice. A noticeable
difference in these two systems is that SIRT2 expression is
increased at the initial stage of pancreatic cancer while the
mouse model has a complete deletion even before tumor
Cancer Cell
Regulation of LDH-A by Acetylation in Cancerdevelopment. Therefore, the functions of both SIRT1 and SIRT2
in cancer development may be context-dependent.
Previous studies have indicated an important role of LDH-A in
tumor initiation and progression (Koukourakis et al., 2006; Le
et al., 2010). LDH-A overexpression in pancreatic b cells led to
increased mitochondrial membrane potential in many carci-
nomas (Ainscow et al., 2000; Chen, 1988). We showed that
LDH-A is significantly increased in pancreatic cancer tissues
compared to adjacent normal tissues. Consistently, LDH-A K5
acetylation was significantly decreased in pancreatic cancer
tissues but not further increased during late stage tumor
progression, indicating that LDH-A acetylation at K5 may play
a role in pancreatic cancer initiation. Our study indicates an
important mechanism of LDH-A regulation by acetylation and
LDH-A K5 acetylation as a potential pancreatic cancer initiation
marker.
EXPERIMENTAL PROCEDURES
LDH-A Enzyme Assay
Flag-LDH-Awas ectopically expressed, immunoprecipitated, and eluted using
250 mg/ml of Flag peptide. The eluent was added to a reaction buffer contain-
ing 0.2M Tris-HCl (pH 7.3), 30 mM pyruvate, and 6.6 mMNADH. The change in
absorbance (340 nm) resulting from NADH oxidation was measured using
a F-4600 fluorescence spectrophotometer (HITACHI).
Genetically Encoding Nε-Acetyllysine in Recombinant Proteins
To generate a homogenously K5-acetylated LDH-A construct, we used
a three-plasmid system as described (Neumann et al., 2008, 2009). This
system allows for the site-specific incorporation of N-acetyllysine by way of
a Methanosarcina barkeri acetyl-lysyl-tRNA synthetase/tRNACUA pair that
responds to the amber codon. We cloned wild-type LDH-A into pTEV-8
(pET-21b as backboned with TEV cleavage site) producing a C-terminal
His6-tagged construct, and incorporated an amber codon at lysine 5 (AAG
to TAG by site-directed mutagenesis). Cells were induced at an OD600 of
0.6 with 0.5 mM IPTG. The amber construct was overexpressed in LB with
spectinomycin (50 mg/ml), kanamycin (50 mg/ml), and ampicillin (150 mg/ml),
in addition to 2 mM N-acetyllysine (Sigma-Aldrich) and 20 mM nicotinamide
at the time of induction. Both LDH-A and K5-acetylated LDH-A protein are
purified for enzyme activity analysis.
Pancreatic Cancer Model by Xenograft
BxPC-3 stable cell lines with LDH-A knockdown and re-expressed shRNA
resistant wild-type or K5Q mutant LDH-A were prepared; 7.5 3 106 cells in
PBS were subcutaneously injected into each of 14 nude mice, purchased
from SLAC. Shanghai. Every mouse was injected LDH-AWT cells on left side
and LDH-AK5Q on right side. Seven weeks later, all mice were sacrificed and
tumors were harvested, followed by photography and weighing. The animal
protocols were approved by the Animal Welfare Committee of Shanghai
Medical College, Fudan University.
Pancreatic Tumor Samples and Immunohistochemistry
Pancreatic tumor samples were acquired from Affiliated Shanghai Tenth
People’s Hospital of Tongji University. A physician obtained informed consent
from the patients. The procedures related to human subjects were approved
by Ethic Committee of the Institutes of Biomedical Sciences (IBS), Fudan
University. Immunohistochemistry (IHC) was performed as previously
described (Lei et al., 2006). To quantify the IHC result of positive staining,
the tissue areas of five ducts (173 mm2) in each sample were microscopically
examined and analyzed by an experienced pathologist. Images were captured
using a charge-coupled device camera and analyzed using Motic Images
Advanced software (version 3.2, Motic China Group). Average of staining
score was calculated by dividing the positive areas with total areas. Data ob-
tained were expressed as mean values ± SD. Differences were considered
significant if the p value was less than 0.05.SUPPLEMENTAL INFORMATION
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